Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001203161 | SCV001374311 | uncertain significance | Chédiak-Higashi syndrome | 2022-07-05 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with glutamine, which is neutral and polar, at codon 530 of the LYST protein (p.Lys530Gln). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with LYST-related conditions. ClinVar contains an entry for this variant (Variation ID: 934716). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002561118 | SCV003546762 | uncertain significance | Inborn genetic diseases | 2021-03-03 | criteria provided, single submitter | clinical testing | The c.1588A>C (p.K530Q) alteration is located in exon 5 (coding exon 3) of the LYST gene. This alteration results from a A to C substitution at nucleotide position 1588, causing the lysine (K) at amino acid position 530 to be replaced by a glutamine (Q). The p.K530Q alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |